Literature DB >> 19536382

An unusual cause of breathlessness in a young man.

Antony Leslie Innasimuthu1, Rajiv Sankarnarayanan, Gopala Krishna B Rao, Rob S Hornung.   

Abstract

Amphetamine abuse is a common problem in the developed world. Cardiomyopathy secondary to amphetamine abuse is rare in the general population. The present report describes a 34-year-old man who presented with shortness of breath. Following further investigations, the cause of his breathlessness was determined to be amphetamine abuse. The incidence of amphetamine abuse and its cardiac sequelae are reviewed. The mechanism of amphetamine-induced dilated cardiomyopathy is analyzed, with further review of its complications and treatment.

Entities:  

Mesh:

Year:  2009        PMID: 19536382      PMCID: PMC2722484          DOI: 10.1016/s0828-282x(09)70109-6

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  4 in total

Review 1.  Recreational drug misuse: issues for the cardiologist.

Authors:  A Ghuran; J Nolan
Journal:  Heart       Date:  2000-06       Impact factor: 5.994

2.  Orthostatic hypotension due to suppression of vasomotor outflow after amphetamine intoxication.

Authors:  A A Smit; W Wieling; A J Voogel; R W Koster; P A van Zwieten
Journal:  Mayo Clin Proc       Date:  1996-11       Impact factor: 7.616

3.  Crystal methamphetamine-associated cardiomyopathy: tip of the iceberg?

Authors:  Mevan Wijetunga; Todd Seto; Joseph Lindsay; Irwin Schatz
Journal:  J Toxicol Clin Toxicol       Date:  2003

4.  Alcohol abuse in patients with dilated cardiomyopathy. Laboratory vs clinical detection.

Authors:  R Y Wang; A I Alterman; J S Searles; A T McLellan
Journal:  Arch Intern Med       Date:  1990-05
  4 in total
  1 in total

1.  Predictors of High Profit and High Deficit Outliers under SwissDRG of a Tertiary Care Center.

Authors:  Tarun Mehra; Christian Thomas Benedikt Müller; Jörk Volbracht; Burkhardt Seifert; Rudolf Moos
Journal:  PLoS One       Date:  2015-10-30       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.